Calidi Biotherapeutics, Inc.
CLDI · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $45 | $449 |
| % Growth | – | -100% | -90% | – |
| Cost of Goods Sold | $0 | $1,256 | $274 | $94 |
| Gross Profit | $0 | -$1,256 | -$229 | $355 |
| % Margin | – | – | -508.9% | 79.1% |
| R&D Expenses | $8,878 | $13,008 | $7,257 | $4,674 |
| G&A Expenses | $12,898 | $15,984 | $15,902 | $6,163 |
| SG&A Expenses | $12,898 | $15,984 | $15,642 | $6,163 |
| Sales & Mktg Exp. | $0 | $0 | -$260 | $0 |
| Other Operating Expenses | $0 | -$1,256 | $0 | $0 |
| Operating Expenses | $21,776 | $27,736 | $22,899 | $10,837 |
| Operating Income | -$21,776 | -$28,992 | -$23,128 | -$10,482 |
| % Margin | – | – | -51,395.6% | -2,334.5% |
| Other Income/Exp. Net | -$419 | -$208 | -$2,288 | $13,880 |
| Pre-Tax Income | -$22,195 | -$29,200 | -$25,416 | $3,398 |
| Tax Expense | $14 | $16 | $11 | $11 |
| Net Income | -$22,143 | -$29,216 | -$25,427 | -$10,933 |
| % Margin | – | – | -56,504.4% | -2,435% |
| EPS | -35.7 | -207.61 | -358.8 | 14.16 |
| % Growth | 82.8% | 42.1% | -2,633.9% | – |
| EPS Diluted | -35.7 | -207.61 | -358.8 | 14.16 |
| Weighted Avg Shares Out | 664 | 140 | 71 | 239 |
| Weighted Avg Shares Out Dil | 664 | 140 | 71 | 239 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $933 | $3,749 | $158 | $614 |
| Depreciation & Amortization | $1,535 | $1,256 | $260 | $156 |
| EBITDA | -$19,727 | -$24,195 | -$24,998 | -$9,450 |
| % Margin | – | – | -55,551.1% | -2,104.7% |